Does higher-dose fundamental HF therapy improve prognosis more than achieving a higher overall GDMT score in patients with HFrEF and HFmrEF?
In patients with HFrEF and HFmrEF, achieving higher doses of fundamental HF therapies may be more prognostically important than simply increasing the overall number of GDMT classes prescribed.
LVEF trajectory at 6 months appears to be a valuable prognostic tool, and higher-dose fundamental HF therapy was more important than achieving a higher overall GDMT score.
Chen et al. (Thu,) studied this question.